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ABSTRACT 
 
Background 
Renal transplant patients of the Northern Territory (NT) of 
Australia, suffer poor transplant outcomes including graft 
rejection, infection and increased mortality, therefore 
requiring stringent immunosuppressive drug assay 
monitoring. Best practice dictates that drug assay results 
should be received within 24 hours and at the most no later 
than 48 hours post blood collection. Assays from the Royal 
Darwin Hospital (RDH) are processed at an interstate 
laboratory, therefore prolonging the time to dosage 
adjustment. 
 
Aims 
To assess the time delay that exists between blood sample 
collection at the Royal Darwin Hospital (RDH) and the faxing 
of results from an interstate laboratory to RDH. 
 
Methods  
We conducted a retrospective audit of immunosuppressive 
drug assay samples and results between the 4
th
 of January 
2013 and the 22
nd
 April 2014. Time delay was divided into 
intervals: T1: Total time between collections to faxing of 
results back to RDH, T2: Time between blood collection, 
sending of samples and reporting at an interstate 
laboratory, T3: Time between results reporting and the 
faxing of results back to RDH. 
 
Results  
A total of 389 drug assays from 49 renal transplant patients 
were analysed. Median times in hours (interquartile ranges) 
were T1=53.48 (31.68-78.55), T2=47.18 (28.80-76.18), 
T3=2.70 (1.87-3.90). 13.3 per cent of the results led to the 
requirement for dosage changes with the potential risk of 
under-dosing or overdosing. 
 
Conclusion 
The long median time delay between sample collection and 
receiving of results illustrates the challenges of 
immunosuppression in this setting and the need for on-site 
immunosuppressive drug assaying. 
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What this study adds:  
1. What is known about this subject?  
Immunosuppressive drug assaying in renal transplants 
patients is required to balance the risk of rejection versus 
the risk of infections and other complications.  
 
2. What new information is offered in this study? 
Remote-regional areas provide significant challenges to 
managing renal transplantation, as interstate laboratory 
drug assaying leads to the risk of increased time to dosage 
adjustment.  
 
 
 190 
 
[AMJ 2016;9(6):189–193] 
 
3. What are the implications for research, policy, or 
practice?  
Provisions should be made for on-site immunosuppressive 
drug assaying for remote and regional areas such as Darwin 
in Northern Australia.  
 
 
Background 
The Northern Territory (NT) bears much of the brunt of 
Chronic Kidney Disease (CKD) in Australia. Among its 
Indigenous population, CKD is 4-10 times higher when 
compared to non-Indigenous Australians. This is principally 
attributed to higher rates of diabetes mellitus, 
hypertension, smoking, infections, glomerular disease and 
low nephron endowment.
1
 
 
Complicating the burden of CKD in the territory is the 
remoteness of its sufferers. Compared to other states and 
territories, 45 per cent of the NT’s population live remotely. 
75 per cent of its Indigenous population live in areas defined 
as remote and very remote.
2
 
 
Renal replacement treatments (RRT) including peritoneal 
dialysis, home haemodialysis and community health centre 
dialysis, is offered, thus diminishing the need to relocate to 
greater centres for treatment for those who can use these 
modalities of treatment. Unfortunately, however, due to 
the many challenges of living remotely and the large burden 
of co-morbidities among Indigenous people, these 
alternatives are offered to a minority of patients. This 
therefore leaves most patients accepting haemodialysis in 
bigger centres in Darwin, Katherine and Alice Springs, often 
at the cost of being separated from their homeland, cultural 
responsibilities, children and spouses.  
 
In a bid to improve both patient outcomes, there has been a 
recent increase in the number of successful renal 
transplantation in the NT. Unpublished data suggests that 
over the last 6 years renal transplants have almost doubled, 
therefore increasing the use of services involved in routine 
transplant care. 
 
Renal transplantation among most patients with end stage 
renal failure (ESRF) is the most effective form of renal 
replacement therapy. It offers improved quality of life, 
reduced morbidity, mortality and economic benefits in most 
patient populations when compared to dialysis.
3-6
 
 
Specifically, renal transplantation compared to 
haemodialysis, is associated with improved patient 
survival
3
. However, when paralleled to non-Indigenous 
transplant patients, Indigenous renal transplant recipients 
suffer higher rates of renal allograft loss and mortality.
4-6 
Data from the Australia and New Zealand Dialysis and 
Transplant (ANZDATA) registry published by McDonald et al. 
in 2004, analysed both graft survival and patient survival at 
5 years post transplantation, between Indigenous and Non 
Indigenous patients. At 5 years post transplantation, graft 
survival of Indigenous transplant recipients was 47.8 per 
cent compared to 80 per cent in non-Indigenous recipients. 
Similarly, at 5 years post transplantation, patient survival 
among Indigenous patients was 61.7 per cent compared to 
88.7 per cent among non-Indigenous patients.
5
 Various 
factors such as increased rates of infection, septicaemia, 
increased plasma cell infiltrates in grafts (thus 
increasing susceptibility to post transplant infection rates 
due to increased immunosuppression burden). Greater 
rates of human leukocyte antigen (HLA) mismatches and 
increased rate of sensitisation prior to transplant among 
Indigenous recipients with increased rates of rejection, 
were attributed to the disparities.
1,4,5 
 
Additionally, poor outcomes in the NT were also attributed 
to the absence of on-sight renal pathologists and of specific 
interest to this report, the absence of on-site 
immunosuppressive drug assay processing.
7,4
 
 
At RDH, immunosuppressive drug assays from patients are 
currently done in interstate laboratories. Patient blood 
samples are collected by pathology at RDH prior to morning 
dose administration. Multiple samples are then sent 
collectively to an interstate laboratory by aeroplane for 
analysis. Once reported at the interstate laboratory, these 
reports are finally faxed back to RDH, for clinicians to 
review.  
 
Often drug assay results take a considerable amount of time 
to return. In some instances local clinicians report reviewing 
patients in transplant clinics 2-3 days post blood sampling, 
without being able to comment on dosage regimes due to 
pending drugs assay results. Best practice dictates that 
immunosuppressive drug assays should be received within 
24 hours and no later than 48 hours post blood collection, 
for the optimum management of renal transplant care. 
 
This audit aimed to assess the time delay that exists 
between blood sample collection at RDH, drug assay 
reporting and the faxing of results from an interstate 
laboratory back to RDH.  
 
Method 
This was a retrospective audit of immunosuppressive drug 
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assay results between the 4
th
 January 2013 and 22
nd
 April 
2014. The audit was registered with the ethics committee of 
the Northern Territory Department of Health and Menzies 
School of Health Research. HREC Reference number: QAAR 
2014-2234.  
 
A renal transplant patient information database and 
medical files were used to extract immunosuppressive drug 
assay results and demographic data.  
 
The following de-identified data was extracted; the dates 
and times blood samples were collected at RDH, the dates 
and times blood drug assays were reported at an interstate 
laboratory, the dates and times drug assay reports were 
faxed back to RDH and finally drug assays whose reports 
were signed by doctors noting the need for dosage changes. 
 
Data analysis occurred by dividing time into the following 
intervals: T1: The total number of hours between collection 
and faxing results back to Darwin, T2: The number of hours 
between blood sample collection in Darwin, sending of 
samples and result reporting at an interstate laboratory and 
T3: The total number of hours between results reporting at 
an interstate laboratory and the faxing of results to Darwin.  
 
Descriptive and exploratory analyses were performed for 
each length of time summarising the data as means and 
their standard deviations (SD) for continuous normally 
distributed variables and medians and interpercentile 
ranges (IR) for data, which was not normally distributed. An 
analysis was performed to assess the association between 
time variables and requirement for dosage changes using 
chi-squared test and fisher’s exact test as appropriate for 
categorical variables and t-test and Wilcoxon-Mann-
Whitney test for continuous data as appropriate. A two-
tailed p-value of p<0.05 was significant. All analyses were 
performed using Stata Version 13.1 (StataCorp, College 
Station, Texas, US) and Microsoft Excel © 2010 Microsoft. 
 
Results 
A total of 389 immunosuppressive drug assay results from 
49 renal transplant patients were audited from the 4
th
 of 
January 2013 to the 22
nd
 of April 2014. The patients 
belonged to 5 different ethnic backgrounds (Table 1). The 
majority of the patients were Indigenous (Aboriginal and 
Torres Strait Islander) and Caucasian, 42.9 per cent and 40.8 
per cent respectively. The mean (SD) age in years was 49.0 
(14.3). Indigenous patients were older than Caucasians with 
mean (SD) ages in years of 48.3 (12.7) and 43.7 (10.5) 
respectively.  
 
The median (IR) number of hours among time intervals 
were T1=53.48 (31.68-78.55), T2=47.18 (28.80-76.18) and 
T3=2.70 (1.87-3.90) (Table 2). The longest time delay was 
between sample collection and analysis in the interstate 
laboratory. This was predominantly contributed to by the 
time taken to transport the samples.  
 
Among the 389 assay results, 13.3 per cent (n=52) required 
dosage changes. The median (IR) number of hours for the 
drug assay results requiring dosage changes were different 
from those who did not require dosage changes but the 
differences were not statistically significant (Table 3); 
T1=42.43(31.53-79.82) versus T1=53.57 (31.68-78.28) 
p=0.938, T2=30.53 (28.82-77.22) versus T2=48.08 (28.80-
75.93), p=0.712 and T3=2.48 (1.83-3.67) versus T3=2.75 
(1.92-3.93), p=0.522. There was no difference in time delay 
by ethnicity.  
 
Discussion 
Best practice for monitoring stable renal transplant patients 
in remote and regional locations such as the NT, would 
require that immunosuppressive drug assay results be 
received within 24 hours and at most no later than 48 hours 
post blood collection. Previous cohort and registry data 
analyses have shown that both patient and graft survival 
among Indigenous renal transplant patients in the NT of 
Australia are poor compared to Non-Indigenous patients 
from the same region.
1,4-6
 The main causes of death and 
graft loss were infections and rejection.
4,5
 This underlines 
the need for comprehensive monitoring of patients’ 
immunosuppression. Maintenance of an appropriate 
balance between the risk of rejection and over-
immunosuppression depends on immunosuppressive drug 
assay screening, in order to avoid graft rejection or 
infections. Receiving results with time delays create delays 
in clinical decision-making.  
 
This audit is the first study assessing the challenges of 
lacking on-site immunosuppressive assay monitoring, in a 
remote-regional centre in Northern Australia. The results 
suggest that a greater than 48 hours median time delay 
exists. A total time from blood sample collection to 
receiving of faxed results of 53.48 hours has significant 
implications for outcomes particularly for those requiring 
treatment of rejection, requiring change of dose or those 
developing graft dysfunction. The decision to manage these 
patients will largely end up being empirical whilst waiting 
for the results, which is not best practice. The data further 
demonstrated many of these hours (47.18 hours), to be 
occupied by the hours between blood sample collection in 
Darwin, sending of samples and results reporting at an 
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interstate laboratory. Conversely, the hours between results 
reporting at the interstate laboratory and the faxing of 
results to Darwin was very short, (2.7 hours) demonstrating 
the possibility of receiving results within 2 to 4 hours if on-
site analysis was established. These results indicate that 
time is lost in the collection of samples in Darwin, the 
sending of sample and reporting at an interstate laboratory, 
and thus provide strong justification for on-sight 
monitoring. A significant number of changes to collection 
and transport of samples have already been implemented 
following the presentation of these results, with the 
eventual aim of setting up an on-site process for analysis. 
 
Among the 13.3 per cent of drug assays that did require 
dosage changes, time delays were not statically different 
from those that did require changes. These results suggest 
there is a problem across all practice regardless of the 
urgency of results. Patients and their clinicians waited long 
times before being able to change to the appropriate and 
safe immunosuppressive doses, which could have 
compromised their grafts and outcomes.  
 
Published literature states that immunosuppressive drug 
assaying is an essential tool in the achievement of the 
optimum balance between therapeutic effects versus 
adverse reactions.
7
 Pharmacological agents such as 
tacrolimus, sirolimus, Everolimus, cyclosporine and 
mycophenolate may exhibit a high degree of ethnic 
pharmacodynamics and pharmacokinetic variability.
8,9
 As 
these are the drugs used in our transplant patients, it is 
prudent that the monitoring of their levels occurs in a timely 
manner. 
  
There are some limitations in this study that should be 
acknowledged. The main limitation being that time was not 
correlated to renal function. This would have allowed 
greater insight into the consequences of delayed dosage 
changes. However, the aim of this study was to assess the 
deviation from the time limits for getting the results back 
and within this limitation the study showed significant 
findings. The study did not differentiate between new 
transplant and old transplant recipients, where patients 
with new transplants are at a time of high risk. Additionally, 
due to the limited data availability to researchers, total time 
was only analysed in the three intervals, where some 
intervals involved multiple steps. Finally, a cost benefit 
analysis comparing the assaying of samples interstate 
versus the assaying of samples locally at RDH was not 
conducted. 
 
Among the 389 immunosuppressive drug assays audited, a 
greater than 48 hours median delay exists. The greatest 
delay in time lies in the sending of samples and the 
processing drug assays at an interstate laboratory. 
Recommendations from this audit have led to a process of 
improving blood sample collection and transport to the 
interstate laboratory whilst a more robust system of on-site 
monitoring is developed. Further work needs to be done to 
assess the effect of time delays on graft function, infection 
episodes, patient outcomes and long term survival of both 
the renal transplants and the patients. 
 
Conclusion 
In order to improve the management of transplant patients 
this audit supports the commencement of on-site drug 
assay analysis in the Top End of the Northern Territory. 
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Table 1: Ethnicity and Gender 
 
 Number Percentage 
Ethnicity    
Asian  3 7.2 
Caucasian  20 40.8 
Indigenous  21 42.9 
Indonesian  2 4.0 
Filipino  3 6.1 
Gender    
Female 17 34.7 
Male 31 65.3 
Total 49 100.00 
  
 
 
 
 
 
Table 2: Summary statistics for the time taken from sample 
collection in Darwin to getting the results from an 
Interstate Laboratory 
 
Time Variable 
(In Hours)  
Number Of Assays Median(IR) 
T1  389.00 53.48 (31.68-78.55) 
T2  389.00 47.18 (28.80-76.18) 
T3  389.00 2.70 (1.87-3.90) 
Legend: 
Time 1 (T1): Hours between collection of samples in Darwin 
and results being faxed from Interstate Laboratory,  
Time 2 (T2): Hours between blood sample collection in 
Darwin, sending of samples and result reporting Interstate 
Laboratory,  
Time 3 (T3): Hours between result reporting in Interstate 
Laboratory and the faxing of results to Darwin 
 
Table 3: Summary statistics for the time in hours taken 
from sample collection to results by whether a dose 
change was required or not 
 
Dose Change 
Required 
Time Number 
Of Assays 
Median (IR) 
(Hours) 
No  
  
  
T1 337.00 53.57 (31.68-78.28) 
T2 337.00 48.08 (28.80-75.93) 
T3 337.00 2.75 (1.92-3.93) 
Yes 
  
  
T1 52.00 42.43 (31.53-79.82) 
T2 52.00 30.53 (28.82-77.22) 
T3 52.00 2.48 (1.83-3.67) 
Total  
  
  
T1 389.00 53.48 (31.68-78.55) 
T2 389.00 47.18 (28.80-76.18) 
T3 389.00 2.70 (1.87-3.90) 
 
